Sugi Predict

Sugi Predict / Compounds / SCHEMBL1782909

SCHEMBL1782909

SCHEMBL1782909

COC(=O)c1ccc(OCc2ccccc2)c(O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.72
▸ LMNA P02545 2/20 0.72
▸ EGFR P00533 2/20 0.62
▸ SRC P12931 1/20 0.59
▸ SMPD1 P17405 2/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ HDAC8 Q9BY41 1/20 0.56
▸ HDAC6 Q9UBN7 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA7 P43166 1/20 0.53
▸ XDH P47989 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ CA14 Q9ULX7 1/20 0.53
▸ MAPT P10636 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21588079 0.89 HPGD (0.68) HPGDLMNAEGFRSMPD1HDAC1
SCHEMBL3245222 0.88 SMPD1 (0.67) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL3960881 0.87 LMNA (0.62) HPGDLMNAEGFRSRCSMPD1
SCHEMBL1561028 0.86 EGFR (0.59) HPGDLMNAEGFRSRCSMN1; SMN2
SCHEMBL17844325 0.86 HPGD (0.57) HPGDLMNAEGFRRAB9ANPC1
SCHEMBL2188210 0.86 SMPD1 (0.76) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL4874871 0.86 LMNA (0.76) HPGDLMNAEGFRSRCSMPD1
SCHEMBL30102539 0.86 LMNA (0.76) HPGDLMNAEGFRSRCSMPD1
SCHEMBL20059720 0.86 LMNA (0.59) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL2063068 0.86 SMN1; SMN2 (0.73) HPGDLMNASMPD1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2026-02-26 — — US disclosed
US-20260035341-A1 FTO INHIBITORS RPXDS CO LTD (CN) 2026-02-05 — — US disclosed
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors GENZYME CORPORATION 2025-12-23 — — US disclosed
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-09-30 — — US disclosed
EP-4561975-A1 FTO INHIBITORS RPXDS Co., Ltd (CN) 2025-06-04 — — EP disclosed
CN-119546566-A FTO inhibitors 瑞璞鑫(苏州)生物科技有限公司 2025-02-28 — — CN disclosed
CN-118638043-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-09-13 — — CN disclosed
US-20240217991-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS GENZYME CORPORATION (US) 2024-07-04 — — US disclosed
CN-118059104-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-05-24 — — CN disclosed
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2024-04-25 — — US disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 — — WO disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 — — WO disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 — — EP disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 — — EP disclosed
US-8609673-B2 Vandetanib derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-12-17 — — US disclosed
US-20110117084-A1 VANDETANIB DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2011-05-19 — — US disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 — — WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 — — US disclosed
WO-2009094211-A1 QUINAZOLINE COMPOUNDS AND METHODS OF TREATING CANCER CONCERT PHARMACEUTICALS INC. (US) 2009-07-30 — — WO disclosed
WO-2009094210-A1 VANDETANIB DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2009-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035341-A1 FTO INHIBITORS FTO, LDLR, GPR119 HPGD 3946/4885LMNA 1168/4885EGFR 897/4885
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, NR5A1, KLK3 HPGD 3321/4885LMNA 1536/4885EGFR 37/4885
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 HPGD 542/4885LMNA 3155/4885EGFR 61/4885
US-20110117084-A1 VANDETANIB DERIVATIVES KDR, VHL, FLT4 HPGD 1690/4885LMNA 4212/4885EGFR 17/4885
US-20240217991-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS CSF1R, CSF3R, IL1RN HPGD 1983/4885LMNA 4858/4885EGFR 85/4885
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors CSF1R, CSF3R, IL1RN HPGD 2696/4885LMNA 4848/4885EGFR 69/4885
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, KLK3, ACP3 HPGD 542/4885LMNA 3155/4885EGFR 61/4885
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 HPGD 246/4885LMNA 1577/4885EGFR 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.